Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis.
Pablo Demelo-RodríguezAna Isabel Farfán-SedanoJosé María PedrajasPilar LlamasPatricia SigüenzaMaría Jesús JarasManuel Quintana-DiazCarmen Fernández-CapitánBehnood BikdeliDavid JiménezManuel Monrealnull nullPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Among patients hospitalized with COVID-19 receiving intermediate- or therapeutic-intensity anticoagulation, a major bleeding event occurred in 5.7%. Use of therapeutic-intensity anticoagulation, critical illness, and elevated D-dimer or ferritin levels at admission were associated with increased risk for major bleeding.